Please use this identifier to cite or link to this item: https://hdl.handle.net/11147/9373
Title: A novel inhibitor for KRASG12C mutant lung carcinoma
Authors: Khan, H. Y.
Li, Y.
Aboukameel, A.
Mpilla, G.
Sexton, R.
Kanbur, Tuğçe
Nagasaka, M.
Çetinkaya, Hakkı
Çağır, Ali
Keywords: KRAS
Lung cancer
Issue Date: 2020
Publisher: International Association for the Study of Lung Cancer
Abstract: Mutations in KRAS are among the most common aberrations in cancer. However, despite considerable research efforts, KRAS remains a challenging therapeutic target. In recent years, there has been a drive to develop KRAS mutant specific drugs. Among the different known mutations, the KRASG12C (glycine 12 to cysteine) has been considered druggable. Studies have shown that due in part to the close proximity of Cysteine 12 to both the nucleotide pocket and the switch regions, thiol-reactive compounds can bind to the active site covalently and inhibit KRASG12C mutation-driven signaling. The absence of this particular cysteine residue in wild-type KRAS makes such an approach very selective towards cancer cells.
URI: https://hdl.handle.net/11147/9373
ISSN: 1556-0864
1556-1380
Appears in Collections:Chemistry / Kimya
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Files in This Item:
File SizeFormat 
PIIS1556086419337591.pdf141.78 kBAdobe PDFView/Open
Show full item record

CORE Recommender

Page view(s)

68
checked on Jul 4, 2022

Download(s)

6
checked on Jul 4, 2022

Google ScholarTM

Check


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.